Introduction and Objective: Continuous glucose monitors (CGMs) are recommended for individuals with diabetes using rapid- or short-acting insulin, but many eligible individuals do not use them. This study compared healthcare costs and utilization between CGM users and non-users.Methods: Claims data from the Mariner Commercial Claims Database (January 1, 2010-April 30, 2022) were analyzed. Adults (≥18 years) with diabetes and at least one claim for rapid- or short-acting insulin (index date) were included. Participants were required to have continuous enrollment for 12 months and had no CGM claims in the prior 6 months. Matched cohorts of CGM users and non-CGM users were compared on healthcare costs at 3-, 6-, 9-, and 12-months and emergency room (ER) and inpatient (IP) utilization at 12-months post-index.Results: The analysis included 938,740 individuals (CGM users = 469,370; non-CGM users = 469,370). CGM users had significantly lower mean total healthcare costs at 6, 9, and 12 months compared to non-users ($3,229-$6,245 vs. $4,031-$7,786; p < 0.01). Costs were slightly higher for CGM users at 3 months, likely reflecting upfront device and supply costs. CGM users also had fewer ER and IP utilization compared to non-CGM users (range = 1.4 – 2.1 days vs. 1.6 – 2.8 days; p < 0.01).Conclusion: The analysis suggests that CGM use significantly lowers healthcare costs and reduces healthcare burden for eligible individuals managing diabetes. Overall, CGMs appear to reduce financial and utilization burdens for both patients and payers.
J. Allaire: Consultant; CCS Medical. A. Masturzo: None. C. Dennis: None.
Source link
Leave a Reply